ATC Group: C10A Lipid modifying agents, plain

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C10A in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C10 Lipid modifying agents
3 C10A Lipid modifying agents, plain

Group C10A contents

Code Title
C10AA HMG CoA reductase inhibitors
C10AB Fibrates
C10AC Bile acid sequestrants
C10AD Nicotinic acid and derivatives
C10AX Other lipid modifying agents

Active ingredients in C10A

Active Ingredient Description
Acipimox

Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.

Alipogene tiparvovec

Alipogene tiparvovec contains the human lipoprotein lipase (LPL) gene variant LPLS447X in a vector. The human LPL gene variant LPLS447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle. Alipogene tiparvovec is injected as a one-time series into the muscle of the lower extremities where it is taken up by myocytes.

Alirocumab

Alirocumab is a fully human IgG1 monoclonal antibody that binds with high affinity and specificity to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

Atorvastatin

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Bempedoic acid

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver.

Bezafibrate

Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism.

Choline fenofibrate
Ciprofibrate

Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol.

Clofibrate
Colesevelam

Colesevelam is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption.

Colestipol

Colestipol is an ion exchange resin which lowers plasma cholesterol through binding with bile acids in the intestinal lumen. It is indicated as adjunctive therapy to diet in the management of patients with elevated cholesterol levels who have not responded adequately to diet.

Colestyramine

Colestyramine resin absorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the faeces. This results in an increased faecal loss of bile acids which leads to an increased oxidation of cholesterol to bile acids and a decrease in serum cholesterol levels and low density lipoprotein serum levels.

Docosahexaenoic acid

Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk (breast milk), fish oil, or algae oil.

Eicosapentaenoic acid

Eicosapentaenoic acid (EPA; also icosapentaenoic acid) is an omega-3 fatty acid. It also has the trivial name timnodonic acid. Eicosapentaenoic acid is a polyunsaturated fatty acid (PUFA) that acts as a precursor for prostaglandin-3 (which inhibits platelet aggregation), thromboxane-3, and leukotriene-5 eicosanoids. Eicosapentaenoic acid is both a precursor and the hydrolytic breakdown product of eicosapentaenoyl ethanolamide (EPEA: C22H35NO2; 20:5,n-3).

Evolocumab

Evolocumab binds selectively to PCSK9 and prevents circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated LDLR degradation. Increasing liver LDLR levels results in associated reductions in serum LDL-cholesterol (LDL-C).

Ezetimibe

Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol.

Fenofibrate

Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.

Fenofibric acid
Fluvastatin

Fluvastatin, a fully synthetic cholesterol-lowering agent, is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Fluvastatin reduces total-C, LDL-C, Apo B, and triglycerides, and increases HDL-C in patients with hypercholesterolaemia and mixed dyslipidaemia.

Gemfibrozil

Gemfibrozil is a lipid regulating agent which regulates lipid fractions. Gemfibrozil stimulates the peripheral lipolysis of triglyceride rich lipoproteins such as VLDL and cholymicrons by stimulation of LPL. Gemfibrozil also inhibits synthesis of VLDL in the liver.

Inclisiran

Inclisiran is a cholesterol-lowering, double-stranded, small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. It is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet.

Lomitapide

Lomitapide directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL. The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C.

Lovastatin

Lovastatin, which is an inactive lactone, is hydrolysed after oral administration to the corresponding β-hydroxyacid. This is the major metabolite and an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyses an early and rate-limiting step in the biosynthesis of cholesterol.

Niceritrol
Omega-3-acid ethyl esters
Pemafibrate

Pemafibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist and activates PPARα by binding to this receptor and regulates the target gene expression, leading to decreased plasma triglyceride (TG) concentration, decreased triglyceride-rich lipoprotein, decreased apolipoprotein (Apo) C-3, and increased HDL-cholesterol.

Pitavastatin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver.

Pravastatin

Pravastatin is a competitive inhibitor of 3-hydroxy–3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme catalyzing the early rate limiting step in cholesterol biosynthesis, and produces its lipid lowering effect in two ways.

Rosuvastatin

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

Simvastatin

Simvastatin has a potent activity in inhibiting HMG-CoA reductase (3-hydroxy–3-ethylglutaryl-CoA-reductase). Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations.

Nicotinic acid

Niacin (nicotinic acid) is an essential B complex Vitamin (B3), whose deficiency results in the clinical syndrome known as pellagra. Nicotinamide (niacinamide), the active ingredient, is the physiologically active form of niacin and is the chemical form of Vitamin B3 found in virtually all multivitamin products. Though nicotinic acid and nicotinamide are so closely related chemically, they differ somewhat in pharmacological properties.

Related product monographs

Title Information Source Document Type  
ASPAVOR Film-coated tablet Web Search MPI, Generic
ATORSTAN Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
CHOLESTAGEL Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC
COLESTID Granule for oral suspension FDA, National Drug Code (US) MPI, US: SPL/Old
COLESTID Granule for oral suspension Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
COLESTID Tablet FDA, National Drug Code (US) MPI, US: SPL/Old
CRESTOR Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
DEZZOLIP Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
EVKEEZA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
EZETIMIBE SANDOZ Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EZETROL Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
EZOLETA Tablet Medicines Authority (MT) MPI, EU: SmPC
FENOFIBRATE Hard capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FLUVASTATIN Capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GLYBERA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
IPOLIPID Hard gelatin capsule / Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
JUXTAPID Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
LACROMID Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
LEQVIO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
LESCOL XL Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
LESTAVOR Film-coated tablet Marketing Authorisation Holder MPI, Generic
LIPANTHYL Penta Film-coated tablet Health Sciences Authority (SG) MPI, Generic
LIPANTIL Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LIPIDIL NT Film coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
LIPITOR Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LIPITOR Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
LIPOFOR Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
LIVALO Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
LIVAZO Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LOJUXTA Hard, capsule European Medicines Agency (EU) MPI, EU: SmPC
LOPID Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MODALIM Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIASPAN Film coated tablet / Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
NILEMDO Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OLBETAM Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OLESTYR Oral suspension Health Products and Food Branch (CA) MPI, CA: SPM
OMACOR Capsule, soft Health Products Regulatory Authority (IE) MPI, EU: SmPC
PRALUENT Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
PRAVACHOL Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
QUESTRAN Powder for oral suspension Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
REPATHA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
SIMCARD Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
SIMVASTATIN Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
STATOL Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
TRICOR Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TRILIPIX Delayed release capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
VASCEPA Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
VAZKEPA Soft capsule European Medicines Agency (EU) MPI, EU: SmPC
WAYLIVRA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ZAFIBRAL Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
ZETIA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ZIENT Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
ZOCOR Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR